LC
EBS icon

Lindbrook Capital’s Emergent Biosolutions EBS Stock Holding History

Lindbrook Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-101
Closed -$966 – 2823
2024
Q4 		$966 Hold
101
– – ﹤0.01% 2487
2024
Q3 		$843 Buy
101
+36
+55% +$327 ﹤0.01% 2539
2024
Q2 		$443 Buy
+65
New +$280 ﹤0.01% 2650
2023
Q4 		– Sell
-210
Closed -$714 – 2725
2023
Q3 		$714 Sell
210
-762
-78% -$4.22K ﹤0.01% 2446
2023
Q2 		$7.14K Buy
972
+867
+826% +$8.04K ﹤0.01% 1642
2023
Q1 		$1.09K Sell
105
-620
-86% -$7.49K ﹤0.01% 2438
2022
Q4 		$8.56K Buy
+725
New +$11.2K ﹤0.01% 1512
2022
Q3 		– Sell
-45
Closed -$1K – 2690
2022
Q2 		$1K Buy
+45
New +$1.54K ﹤0.01% 2209

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lindbrook Capital's EBS Position: Q1 2025 in Review

Lindbrook Capital sold out of Emergent Biosolutions (EBS) in Q1 2025, closing a stake of 101 shares — an estimated $966 sold.

Lindbrook Capital first reported a position in EBS in Q2 2022 and held it in 8 quarters. The position peaked at $8.56K in Q4 2022. 160 funds tracked by Wall St. Rank hold EBS as of Q1 2025.

  • Lindbrook Capital reported no remaining Emergent Biosolutions position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 101 Emergent Biosolutions shares in Q1 2025, an estimated $966.
  • Lindbrook Capital first reported a position in Emergent Biosolutions in Q2 2022 and held it in 8 quarters.
  • Lindbrook Capital's Emergent Biosolutions position peaked at $8.56K in Q4 2022.
  • 160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.